IN BRIEF: Pfizer wins European approval for prostate cancer treatment
08 Enero 2024 - 12:09PM
Alliance News
York City-based
pharmaceutical firm - European Commission approves TALZENNA
(talazoparib), an oral poly ADP-ribose pol ...
Subscribe now to see this Premium News
article from
Alliance News Professional covers every UK
stock in your portfolio. It goes beyond regulatory news and free
web services to give your investment decisions an edge over the
crowd.
- In The
Know - Management and analyst comments that go beyond company
announcements.
- Flash headlines on all 2,400 London-listed companies before the
news hits the open web.
- Broker Ratings - The
earliest tip-offs, many before the market opens.
- Economic data and central bank flashes from UK, US and
eurozone.
- Taking
AIM - Up to the minute market commentary on AIM stocks.
- Over 500 news items per trading day for just £39.60 per month,
and cancel at any time.
Call us on +44 (0) 203 8794 460 to get
started.
Pfizer (LSE:0Q1N)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Pfizer (LSE:0Q1N)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024